سعر جادينو 90 مجم 30 قرص 2026

Deferasirox 90 mg film-coated tablets (Novartis), an oral iron chelator for chronic iron overload.

• Chronic iron overload due to blood transfusions (transfusional haemosiderosis) in patients 2 years of age and older.Population: Patients >= 2 yearsDailyMed (U.S. National Library of Medicine)
• Chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassaemia (LIC >= 5 mg Fe/g dw and serum ferritin > 300 mcg/L).Population: Patients >= 10 years with NTDTDailyMed (U.S. National Library of Medicine)

• Transfusional iron overload: most frequent (> 5%) diarrhoea, vomiting, nausea, abdominal pain, skin rashes and increased serum creatinine; NTDT: diarrhoea, rash and nausea.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• eGFR less than 40 mL/min/1.73 m2.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Poor performance status; high-risk myelodysplastic syndromes; advanced malignancies.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Platelet counts less than 50 x 10^9/L.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: may cause acute renal failure (including fatal cases), hepatic injury including hepatic failure, and gastrointestinal haemorrhage (especially in elderly patients with advanced haematologic malignancies and/or low platelets).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Bone marrow suppression, hypersensitivity, severe skin reactions, skin rash, auditory and ocular abnormalities, and overchelation (interrupt if ferritin falls below 500 mcg/L) are described in the label.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Aluminium-containing antacidsDo not take deferasirox with aluminium-containing antacid preparations.DailyMed (U.S. National Library of Medicine)
• CYP3A4 substrates (e.g., cyclosporine, simvastatin, hormonal contraceptives, midazolam)Deferasirox may induce CYP3A4 and decrease substrate concentrations; monitor for reduced effectiveness.DailyMed (U.S. National Library of Medicine)
• RepaglinideDeferasirox increases repaglinide exposure; consider repaglinide dose reduction and monitor blood glucose.DailyMed (U.S. National Library of Medicine)

• No studies in pregnant women; in rats, decreased offspring viability and renal anomalies in male offspring at about or below the human dose. Use only if the potential benefit justifies the potential fetal risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human milk data; deferasirox is excreted in rat milk. Decide whether to discontinue breastfeeding or the drug, considering its importance to the mother.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Deferasirox: Orally active tridentate chelator highly selective for ferric iron; two molecules bind one iron atom and the complex is excreted mainly in the faeces.